within Pharmacolibrary.Drugs.ATC.A;

model A02BB02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.15,
    Cl             = 0.8333333333333334,
    adminDuration  = 600,
    adminMass      = 0.0002,
    adminCount     = 1,
    Vd             = 0.013,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Enprostil is a synthetic prostaglandin E2 analogue that acts as a gastroprotective agent, primarily improving gastric mucosal defense and inhibiting gastric acid secretion. It was developed for the treatment and prevention of gastric and duodenal ulcers. Enprostil is not widely approved for clinical use today.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters in healthy adult subjects, as no original clinical PK data are available in the literature.</p><h4>References</h4><ol><li>K L Goa, J P Monk,Enprostil. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of peptic ulcer disease.,Drugs,1987<a href='https://pubmed.ncbi.nlm.nih.gov/3121276/'>https://pubmed.ncbi.nlm.nih.gov/3121276/</a></li><li>H Vanhanen, T A Miettinen,Enprostil impairs cholesterol and fat absorption.,Scandinavian journal of gastroenterology,1995<a href='https://pubmed.ncbi.nlm.nih.gov/7701247/'>https://pubmed.ncbi.nlm.nih.gov/7701247/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A02BB02;
